MedTrace Logo

The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

NCT00336115 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2007-10-23

No results posted yet for this study

Summary

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.

Conditions

  • Pertussis

Interventions

BIOLOGICAL

Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)

Sponsors & Collaborators

  • Queen Elizabeth II Health Sciences Centre

    lead OTHER

Principal Investigators

  • Monique L MacFarlane Conrad, MSc · Dalhousie University Medical School

  • Shelly McNeil, MD · Queen Elizabeth II Health Sciences Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2008-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336115 on ClinicalTrials.gov